Uncategorized
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has notified the Company in a letter that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824. KVD824 is KalVista’s oral product candidate being developed for proph